Clinical trial · Interventional
FDG PET Imaging in Diagnosing Patients With Glioblastoma
Dual Time Point FDG PET Imaging Optimization for the Evaluation of Glioblastoma
NCT02885272CI-TRIAL-00059798completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This early phase I trial studies the how well fluorodeoxyglucose F-18 (FDG) positron emission tomography (PET) imaging works in diagnosing patients with confirmed or suspected glioblastoma. Diagnostic procedures, such as FDG PET, may help find and diagnose glioblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Glioblastoma | Brain Glioblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography | Procedure | — | UNRESOLVED |
| Fludeoxyglucose F-18 | Radiation | — | UNRESOLVED |
| Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
| Positron Emission Tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (PET/CT)
- description
- Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.
- interventionNames
- Procedure: Computed Tomography
- Radiation: Fludeoxyglucose F-18
- Procedure: Magnetic Resonance Imaging
- Procedure: Positron Emission Tomography
Primary outcomes (5)
- measure
- Differences in length-beam ratio
- timeFrame
- Up to 2 years
- description
- Will be tested via paired t-test after appropriate transformation.
- measure
- Quantitative parametric maps based on biophysical principles or pharmacokinetic modeling
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Adult (\> 19 years of age) patients with biopsy proven (as opposed to being status post definitive surgical therapy) or highly suspected glioblastoma of the brain * Cases without prior biopsy will be chosen based upon consensus of a MD Anderson faculty neuroradiologist and neurosurgeon for high probability of representing a glioblastoma * T1 post contrast lesion size greater than or equal to 10 mm Exclusion Criteria: * Children * Definitive/gross total lesion resection * Prior brain cancer * Prior whole brain radiation * Known history of cerebrovascular disease, dementia or prior non-mild traumatic brain injury * Known allergy to FDG or gadolinium based contrast agents * Pregnant women are excluded
References
Publications (0)
Data not yet available
No reference posted for this study.